Keyphrases
Axonal Loss
16%
Ceramide
16%
Ceramide-1-phosphate
16%
Clinical Course
16%
CNS Damage
16%
CNS Disorders
16%
Dihydroceramide
33%
Hexosylceramide
16%
HPLC-mass Spectrometry
16%
Immune-mediated Demyelination
16%
Inactive Phase
16%
Inflammatory Process
16%
Lipid Profile
16%
Main Phase
16%
Metabolic Pathway
16%
Modification Patterns
16%
MS Lesions
16%
Multiple Sclerosis
100%
Multiple Sclerosis Lesions
100%
Multiple Sclerosis Treatment
16%
Neurodegenerative Processes
16%
Neurological Diseases
16%
New Biomarkers
16%
Normal-appearing White Matter
66%
Pathomechanism
16%
Phosphate
16%
Plaque
33%
Prognostic Strategies
16%
Progressive Form
16%
Progressive Stages
16%
Sphingolipidomics
16%
Sphingolipids
100%
Therapeutic Strategies
16%
Tumefactive multiple Sclerosis
16%
Medicine and Dentistry
Biological Marker
30%
Central Nervous System Disease
10%
Ceramide
10%
Ceramide 1 Phosphate
10%
Demyelination
10%
Disease
10%
Disease Course
10%
High-Performance Liquid Chromatography
10%
Metabolism
10%
Multiple Sclerosis
100%
Neurologic Disease
10%
Phosphate
10%
Sphingolipid
100%
Tandem Mass Spectrometry
10%
Biochemistry, Genetics and Molecular Biology
Ceramide
50%
High-Performance Liquid Chromatography
25%
Lipid Profile
25%
Metabolic Pathway
25%
Sphingolipid
100%
Tandem Mass Spectrometry
25%
Immunology and Microbiology
High Performance Liquid Chromatography
10%
Metabolism
10%
Multiple Sclerosis
100%
Tandem Mass Spectrometry
10%
White Matter
40%